The elvitegravir Quad pill: the first once-daily dual-target anti-HIV tablet

Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection

(2011) Calvin Cohen et al.   AIDS

Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143

(2011) Mathieu Métifiot et al.   AIDS

Molecular Dynamics Approaches Estimate the Binding Energy of HIV-1 Integrase Inhibitors and Correlate withIn VitroActivity

(2011) Barry C. Johnson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection

(2011) JK Rockstroh et al.   HIV MEDICINE

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial

(2011) Joseph J Eron et al.   LANCET INFECTIOUS DISEASES

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

(2011) Jean-Michel Molina et al.   LANCET INFECTIOUS DISEASES

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

(2011) Jan van Lunzen et al.   LANCET INFECTIOUS DISEASES

Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)

(2011) S. Hare et al.   MOLECULAR PHARMACOLOGY

Interfacial inhibitors: targeting macromolecular complexes

(2011) Yves Pommier et al.   NATURE REVIEWS DRUG DISCOVERY

Potent and Sustained Antiviral Response of Raltegravir-based Highly Active Antiretroviral Therapy in HIV Type 1-infected Children and Adolescents

(2011) Verónica Briz et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Biochemical and Pharmacological Analyses of HIV-1 Integrase Flexible Loop Mutants Resistant to Raltegravir

(2010) Mathieu Métifiot et al.   BIOCHEMISTRY

Retroviral intasome assembly and inhibition of DNA strand transfer

(2010) Stephen Hare et al.   NATURE

Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection

(2009) Martin Markowitz et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Comparison of Raltegravir and Elvitegravir on HIV-1 Integrase Catalytic Reactions and on a Series of Drug-Resistant Integrase Mutants†

(2008) Jessica Marinello et al.   BIOCHEMISTRY